แหล่งสืบค้นข้อมูลจาก Micromedex
... แหล่ งสืบค้ นข้ อมูลจาก Micromedex A) SENNA: B) CLASS: LAXATIVE C) DOSAGE: 1) IMPORTANT NOTE: Dosing of herbal preparations is highly dependent on a variety of factors, such as growing and harvesting conditions, plant parts and extraction methods used and the dosage form chosen by the manufacturer. ...
... แหล่ งสืบค้ นข้ อมูลจาก Micromedex A) SENNA: B) CLASS: LAXATIVE C) DOSAGE: 1) IMPORTANT NOTE: Dosing of herbal preparations is highly dependent on a variety of factors, such as growing and harvesting conditions, plant parts and extraction methods used and the dosage form chosen by the manufacturer. ...
2015 ESC Guidelines for the diagnosis and management of
... ESC Working Groups: Cardiovascular Pharmacotherapy, Cardiovascular Surgery, Grown-up Congenital Heart Disease, Myocardial and Pericardial Diseases, Pulmonary Circulation and Right Ventricular Function, Valvular Heart Disease. The content of these European Society of Cardiology (ESC) Guidelines has b ...
... ESC Working Groups: Cardiovascular Pharmacotherapy, Cardiovascular Surgery, Grown-up Congenital Heart Disease, Myocardial and Pericardial Diseases, Pulmonary Circulation and Right Ventricular Function, Valvular Heart Disease. The content of these European Society of Cardiology (ESC) Guidelines has b ...
Imipramine Hydrochloride Imipramine Pamoate
... Major Depressive Disorder There is a wide range of oral dosage requirements, and dosage must he carefully individualized. Initial dosages of imipramine should be low and generally range from 75-100 mg daily, depending on the severity of the condition being treated. Dosage may be gradually adjusted t ...
... Major Depressive Disorder There is a wide range of oral dosage requirements, and dosage must he carefully individualized. Initial dosages of imipramine should be low and generally range from 75-100 mg daily, depending on the severity of the condition being treated. Dosage may be gradually adjusted t ...
ARBS (if unable to tolerate ACE`s) with evidence in Heart Failure
... Step 1: Take with food Step 2: Take at night Step 3: D/C if N/V persists And switch to ARB ...
... Step 1: Take with food Step 2: Take at night Step 3: D/C if N/V persists And switch to ARB ...
Cetrotide® 0.25 mg
... controlled clinical studies utilizing active comparators. A third non-comparative clinical study evaluated only the multiple 0.25 mg dose regimen of Cetrotide®. The ovarian stimulation treatment with recombinant FSH or human menopausal gonadotropin (hMG) was initiated on day 2 or 3 of a normal mens ...
... controlled clinical studies utilizing active comparators. A third non-comparative clinical study evaluated only the multiple 0.25 mg dose regimen of Cetrotide®. The ovarian stimulation treatment with recombinant FSH or human menopausal gonadotropin (hMG) was initiated on day 2 or 3 of a normal mens ...
An anti-epileptic and anti-Parkinson`s disease agent zonisamide
... For peripheral neuropathies due to injuries and some other causes, local administrations of the nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), laminins, and cadherin-11 are reported to be effective. Short half-lives and requirement of local administration, however, make the cli ...
... For peripheral neuropathies due to injuries and some other causes, local administrations of the nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), laminins, and cadherin-11 are reported to be effective. Short half-lives and requirement of local administration, however, make the cli ...
SWOV Fact sheet Driving under the influence of drugs and
... differences in the effects even within a single type of drug. The effect of cannabis, for example, is that the user becomes ‘high’ or ‘stoned’ and experiences feelings of euphoria, relaxation and lethargy. Their reaction time increases, their coordination decreases, and their memory is affected. As ...
... differences in the effects even within a single type of drug. The effect of cannabis, for example, is that the user becomes ‘high’ or ‘stoned’ and experiences feelings of euphoria, relaxation and lethargy. Their reaction time increases, their coordination decreases, and their memory is affected. As ...
Cetrotide® 0.25 mg (cetrorelix acetate for injection) FOR
... Cetrotide® competes with natural GnRH for binding to membrane receptors on pituitary cells and thus controls the release of LH and FSH in a dose-dependent manner. The onset of LH suppression is approximately one hour with the 3 mg dose and two hours with the 0.25 mg dose. This suppression is mainta ...
... Cetrotide® competes with natural GnRH for binding to membrane receptors on pituitary cells and thus controls the release of LH and FSH in a dose-dependent manner. The onset of LH suppression is approximately one hour with the 3 mg dose and two hours with the 0.25 mg dose. This suppression is mainta ...
DESIGN, DEVELOPMENT AND OPTIMIZATION OF FAST DISSOLVING TABLET OF
... induced emesis. The adult dose is 8 mg and its metabolites are excreted in urine with about 10% of unchanged drug and having 67% of bioavailability through oral route. In the present investigation FDT of Ondansetron HCl was developed by maximizing the porous structure of the tablet matrix, incorpora ...
... induced emesis. The adult dose is 8 mg and its metabolites are excreted in urine with about 10% of unchanged drug and having 67% of bioavailability through oral route. In the present investigation FDT of Ondansetron HCl was developed by maximizing the porous structure of the tablet matrix, incorpora ...
Neonatal Unit Oral and Intravenous Drug Administration Workbook
... Complete an Incident Reporting Form (IRFs) and also photocopy the relevant paperwork e.g. drug charts. Use the Datix reporting system which is found on the desk top dashboard on any network computer. ...
... Complete an Incident Reporting Form (IRFs) and also photocopy the relevant paperwork e.g. drug charts. Use the Datix reporting system which is found on the desk top dashboard on any network computer. ...
INTENDED USE SUMMARY AMPHETAMINE (AMP 1,000
... propoxyphene can be from 50-75% as potent as oral codeine. Darvocet™, one of the most common brand names for the drug, contains 50-100 mg of propoxyphene napsylate and 325-650 mg of acetaminophen. Peak plasma concentrations of propoxyphene are achieved from 1 to 2 hours post dose. In the case of ove ...
... propoxyphene can be from 50-75% as potent as oral codeine. Darvocet™, one of the most common brand names for the drug, contains 50-100 mg of propoxyphene napsylate and 325-650 mg of acetaminophen. Peak plasma concentrations of propoxyphene are achieved from 1 to 2 hours post dose. In the case of ove ...
PATTON BOGGS, L.L. P. 1660
... or other substance, or immediate precursor, included in schedule I, II, III, IV, or V of part B of this subchapter. These five schedules of controlled substances are a part of 21 U.s.c. S812. In the United Statesr there are three criteria which must be considered when determining whether to place a ...
... or other substance, or immediate precursor, included in schedule I, II, III, IV, or V of part B of this subchapter. These five schedules of controlled substances are a part of 21 U.s.c. S812. In the United Statesr there are three criteria which must be considered when determining whether to place a ...
Preparation and Characterisation of Mucoadhesive Nasal Gel of
... The aim of the present study is to prepare and evaluate mucoadhesive nasal gels of venlafaxine hydrochloride. Mucoadhesive nasal gels were prepared using polymers like carbopol 934 and sodium alginate and characterized in terms of viscosity, texture profile analysis, ex vivo drug permeation profiles ...
... The aim of the present study is to prepare and evaluate mucoadhesive nasal gels of venlafaxine hydrochloride. Mucoadhesive nasal gels were prepared using polymers like carbopol 934 and sodium alginate and characterized in terms of viscosity, texture profile analysis, ex vivo drug permeation profiles ...
SANTEN RECEIVES FDA APPROVAL OF IQUIX
... fluoroquinolone active against a broad spectrum of Gram-positive and Gram-negative ocular pathogens. Levofloxacin's high solubility, at neutral pH, allows the solution to be formulated with a concentration of active drug (1.5%), three times higher than any other ophthalmic fluoroquinolone on the mar ...
... fluoroquinolone active against a broad spectrum of Gram-positive and Gram-negative ocular pathogens. Levofloxacin's high solubility, at neutral pH, allows the solution to be formulated with a concentration of active drug (1.5%), three times higher than any other ophthalmic fluoroquinolone on the mar ...
Regina Conde
... altered states of consciousness (ASC). These variables were also found to be significantly altered from the effects of MDMA. The change in mood had the most profound effect. They found that the level of depersonalization and derealization were altered in relation to mood. These effects caused the su ...
... altered states of consciousness (ASC). These variables were also found to be significantly altered from the effects of MDMA. The change in mood had the most profound effect. They found that the level of depersonalization and derealization were altered in relation to mood. These effects caused the su ...
Biomaterials Week 7
... Degradable implant that is designed to act as an artificial extracellular matrix by providing space for cells to grow into and recognize into functional tissue Man made implantable prostheses do not function as well as the native tissue Or maintain the functionality of native tissue over long pe ...
... Degradable implant that is designed to act as an artificial extracellular matrix by providing space for cells to grow into and recognize into functional tissue Man made implantable prostheses do not function as well as the native tissue Or maintain the functionality of native tissue over long pe ...
Update and trends on pharmacokinetic studies in patients
... Both agencies agree there are certain situations when a pharmacokinetic renal impairment study may not be required (Table 2) [2,3]. These circumstances include drugs that are gaseous or volatile in nature and excreted by the lungs. Single-dose administration of a drug may also negate the need for a ...
... Both agencies agree there are certain situations when a pharmacokinetic renal impairment study may not be required (Table 2) [2,3]. These circumstances include drugs that are gaseous or volatile in nature and excreted by the lungs. Single-dose administration of a drug may also negate the need for a ...
srija
... The formulation and development of novel drug delivery system with the nature of enhancing the effectiveness of existing of drug is an ongoing process in pharmaceutical research. Since there are many types of drug delivery systems that have been developed. The microemulsion concept was introduced in ...
... The formulation and development of novel drug delivery system with the nature of enhancing the effectiveness of existing of drug is an ongoing process in pharmaceutical research. Since there are many types of drug delivery systems that have been developed. The microemulsion concept was introduced in ...
Slide
... Determine a set of candidate dose response models: (e.g. emax, logistic, linear, quadratic, …) For each candidate model, determine the corresponding contrast test, a linear combination of the means that best reflects the assumed dose response curves. ...
... Determine a set of candidate dose response models: (e.g. emax, logistic, linear, quadratic, …) For each candidate model, determine the corresponding contrast test, a linear combination of the means that best reflects the assumed dose response curves. ...
Data Sheet
... In general, patients with bronchospastic diseases should not be given beta-blockers, including Lopresor. However, because of its relative cardioselectivity, oral Lopresor may be administered with caution to patients with mild or moderate bronchospastic diseases who do not respond to, or cannot toler ...
... In general, patients with bronchospastic diseases should not be given beta-blockers, including Lopresor. However, because of its relative cardioselectivity, oral Lopresor may be administered with caution to patients with mild or moderate bronchospastic diseases who do not respond to, or cannot toler ...
Neuman
... and efficacy of GHB as a treatment for narcolepsy indications,42 though as Dr. Scharf concedes, because his was an open label trial – meaning no placebos were used – the report was of limited utility in the development of the drug.43 Subsequently, because of the high cost associated with a treatment ...
... and efficacy of GHB as a treatment for narcolepsy indications,42 though as Dr. Scharf concedes, because his was an open label trial – meaning no placebos were used – the report was of limited utility in the development of the drug.43 Subsequently, because of the high cost associated with a treatment ...
Hydroquinine hydrobromide and hypoglycaemia
... Netherlands for the treatment of nocturnal cramps when treatment with drugs is considered necessary. It is available in the Netherlands since March 1990 as an over-the-counter drug with a dose of 200 mg with the evening meal and a further 100 mg at bedtime for 14 days. According to the Summary of Pr ...
... Netherlands for the treatment of nocturnal cramps when treatment with drugs is considered necessary. It is available in the Netherlands since March 1990 as an over-the-counter drug with a dose of 200 mg with the evening meal and a further 100 mg at bedtime for 14 days. According to the Summary of Pr ...
News Virginia Board of Pharmacy
... Some of these security systems were installed with a 2G-compatible Global System for Mobile communications device that can only communicate via the 2G wireless network. Therefore, when the 2G sunset occurs by January 1, 2017, these security systems will no longer be able to communicate alarm signals ...
... Some of these security systems were installed with a 2G-compatible Global System for Mobile communications device that can only communicate via the 2G wireless network. Therefore, when the 2G sunset occurs by January 1, 2017, these security systems will no longer be able to communicate alarm signals ...
Pharmacokinetics of Intravenous Lorazepam in Pediatric Patients
... Study design Ten hospitals in the Pediatric Emergency Care Applied Research Network enlisted patients 3 months to 17 years with convulsive SE (status cohort) or for a traditional pharmacokinetics study (elective cohort). Sparse sampling was used for the status cohort, and intensive sampling was used ...
... Study design Ten hospitals in the Pediatric Emergency Care Applied Research Network enlisted patients 3 months to 17 years with convulsive SE (status cohort) or for a traditional pharmacokinetics study (elective cohort). Sparse sampling was used for the status cohort, and intensive sampling was used ...
Pharmacokinetics
Pharmacokinetics, sometimes abbreviated as PK (from Ancient Greek pharmakon ""drug"" and kinetikos ""moving, putting in motion""; see chemical kinetics), is a branch of pharmacology dedicated to determining the fate of substances administered externally to a living organism. The substances of interest include pharmaceutical agents, hormones, nutrients, and toxins. It attempts to discover the fate of a drug from the moment that it is administered up to the point at which it is completely eliminated from the body.Pharmacokinetics describes how the body affects a specific drug after administration through the mechanisms of absorption and distribution, as well as the chemical changes of the substance in the body (e.g. by metabolic enzymes such as cytochrome P450 or glucuronosyltransferase enzymes), and the effects and routes of excretion of the metabolites of the drug. Pharmacokinetic properties of drugs may be affected by elements such as the site of administration and the dose of administered drug. These may affect the absorption rate. Pharmacokinetics is often studied in conjunction with pharmacodynamics, the study of a drug's pharmacological effect on the body.A number of different models have been developed in order to simplify conceptualization of the many processes that take place in the interaction between an organism and a drug. One of these models, the multi-compartment model, gives the best approximation to reality; however, the complexity involved in using this type of model means that monocompartmental models and above all two compartmental models are the most-frequently used. The various compartments that the model is divided into are commonly referred to as the ADME scheme (also referred to as LADME if liberation is included as a separate step from absorption): Liberation - the process of release of a drug from the pharmaceutical formulation. See also IVIVC. Absorption - the process of a substance entering the blood circulation. Distribution - the dispersion or dissemination of substances throughout the fluids and tissues of the body. Metabolization (or biotransformation, or inactivation) – the recognition by the organism that a foreign substance is present and the irreversible transformation of parent compounds into daughter metabolites. Excretion - the removal of the substances from the body. In rare cases, some drugs irreversibly accumulate in body tissue.The two phases of metabolism and excretion can also be grouped together under the title elimination.The study of these distinct phases involves the use and manipulation of basic concepts in order to understand the process dynamics. For this reason in order to fully comprehend the kinetics of a drug it is necessary to have detailed knowledge of a number of factors such as: the properties of the substances that act as excipients, the characteristics of the appropriate biological membranes and the way that substances can cross them, or the characteristics of the enzyme reactions that inactivate the drug.All these concepts can be represented through mathematical formulas that have a corresponding graphical representation. The use of these models allows an understanding of the characteristics of a molecule, as well as how a particular drug will behave given information regarding some of its basic characteristics. Such as its acid dissociation constant (pKa), bioavailability and solubility, absorption capacity and distribution in the organism.The model outputs for a drug can be used in industry (for example, in calculating bioequivalence when designing generic drugs) or in the clinical application of pharmacokinetic concepts. Clinical pharmacokinetics provides many performance guidelines for effective and efficient use of drugs for human-health professionals and in veterinary medicine.